Tuberculosis (TB) remains a leading infectious cause of death among children globally. In 2022, the World Health Organization (WHO) reported 1.3 million new TB cases among children under 15 years — accounting for 11% of all global TB cases — and an estimated 217,000 TB-related deaths in this age group. Unlike adults, children under 5 years face heightened vulnerability due to immature immune systems, rapid disease progression, and diagnostic limitations. This article presents clinically accurate, up-to-date information on TB in children, drawing from WHO 2023 guidelines, the American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA)/Centers for Disease Control and Prevention (CDC) joint clinical practice recommendations, and peer-reviewed data from The Lancet Infectious Diseases and Pediatric Infectious Disease Journal. We detail causative pathogens, age-stratified symptom profiles, gold-standard diagnostics including Xpert MTB/RIF Ultra and line probe assays (LPAs), evidence-based treatment regimens such as the 4-month BPaLM (bedaquiline–pretomanid–linezolid–moxifloxacin) for drug-resistant TB, and prevention protocols validated across high-burden settings like India, South Africa, and Indonesia.
Understanding Pediatric Tuberculosis: The Causative Agent and Transmission
Tuberculosis in children is caused almost exclusively by Mycobacterium tuberculosis, a slow-growing, aerobic, acid-fast bacillus. While M. bovis and M. africanum can rarely cause pediatric TB, they account for less than 1% of cases globally. Transmission occurs via inhalation of aerosolized droplet nuclei — generated when an infectious adult or adolescent with pulmonary or laryngeal TB coughs, sneezes, or speaks. These particles measure 1–5 micrometers in diameter and remain suspended in air for hours. A single cough can generate up to 3,000 infectious droplets; prolonged exposure in poorly ventilated indoor spaces significantly increases infection risk.
Children are not primary transmitters. According to a 2021 meta-analysis published in Clinical Infectious Diseases, only 2.4% of pediatric TB cases (ages 0–4 years) were found to be epidemiologically linked to another child — compared to 87% linked to adult household contacts. This reflects lower bacillary load, reduced cough strength, and infrequent cavitary lung disease in young children. Consequently, identifying and treating infectious adult index cases remains the cornerstone of pediatric TB prevention.
Primary Infection vs. Reactivation
Upon inhalation, M. tuberculosis is phagocytosed by alveolar macrophages but resists intracellular killing. In immunocompetent children, this typically triggers a cell-mediated immune response within 2–10 weeks, forming a granuloma — the hallmark of latent TB infection (LTBI). Up to 90% of infected children under 5 years will remain asymptomatic with LTBI. However, infants and toddlers face markedly higher progression risk: 40–50% of infants infected before age 1 develop active TB within one year, versus 5–10% of older children and adolescents.
Risk Factors for Progression to Active Disease
Several biological and environmental factors elevate progression risk:
- HIV co-infection: Increases annual TB incidence by 20-fold; 36% of HIV-positive children in sub-Saharan Africa develop active TB within 12 months of M. tuberculosis exposure
- Malnutrition: Weight-for-height z-score < −2 increases risk 3.2× (WHO 2022 Global TB Report)
- Diabetes mellitus: Prevalence rising among adolescents; confers 3× higher TB risk
- Recent measles infection: Impairs T-cell immunity for up to 2–3 years
- Household crowding: >3 persons per room correlates with 2.7× increased TB incidence in urban Indian cohorts (ICMR 2020 study)
Recognizing Symptoms: Age-Specific Clinical Presentations
Pediatric TB manifests differently across developmental stages due to anatomical, immunological, and behavioral differences. Accurate recognition hinges on understanding these patterns — because symptoms are often nonspecific and easily mistaken for viral illness or pneumonia.
Infants (<12 months)
In this group, TB frequently presents as disseminated disease. Key signs include persistent fever (>2 weeks), failure to thrive (weight loss or <5th percentile gain), lethargy, poor feeding, and respiratory distress. A 2019 multicenter study across 12 hospitals in Kenya, Zambia, and Malawi found that 78% of infants with confirmed TB had hepatosplenomegaly, while 63% exhibited lymphadenopathy. Meningitis occurs in 15–20% of infant TB cases — often with subtle onset: bulging fontanelle, irritability, or high-pitched crying rather than classic neck stiffness.
Young Children (1–5 years)
This cohort commonly develops pulmonary TB with atypical radiographic features. Symptoms include chronic cough (>2 weeks), night sweats, pallor, and recurrent febrile episodes. Unlike adults, cavitation is rare (<5% on chest X-ray); instead, hilar or mediastinal lymphadenopathy dominates — visible in 85% of cases on posterior-anterior CXR. The WHO’s 2023 pediatric TB algorithm emphasizes that a persistent cough plus weight loss or failure to thrive warrants immediate investigation, even without fever.
School-Age Children and Adolescents (6–15 years)
Older children increasingly resemble adults clinically. Pulmonary involvement includes productive cough, hemoptysis (in 12–18%), and pleural effusion (detected in 22% of confirmed cases in a South African cohort). Extrapulmonary TB rises with age: lymph node TB (35%), bone/joint TB (11%), and genitourinary TB (7%). Adolescents aged 12–15 show cavitation rates of 41%, per data from the TB REACH initiative (2021–2023).
Diagnostic Challenges and Evidence-Based Tools
Diagnosing TB in children is notoriously difficult due to paucibacillary disease, inability to produce sputum reliably, and low sensitivity of conventional methods. Culture remains the reference standard but requires 2–8 weeks and yields positive results in only 30–40% of pediatric pulmonary cases.
Molecular Diagnostics: Xpert Ultra and Line Probe Assays
The WHO-endorsed Xpert MTB/RIF Ultra assay (Cepheid, USA) detects M. tuberculosis DNA and rifampicin resistance in under 2 hours. Its sensitivity in pediatric sputum samples is 65–72%, but improves to 89% in gastric aspirates and 93% in nasopharyngeal aspirates (per 2022 Cochrane Review). For children unable to expectorate, induced sputum collection using nebulized hypertonic saline (3–5% NaCl) achieves diagnostic yield comparable to gastric lavage — with success rates of 76% in children aged 2–5 years (study conducted at Christian Medical College, Vellore, India).
Line probe assays (LPAs), such as the GenoType MTBDRplus VER 2.0 (Hain Lifescience, Germany), detect mutations associated with rifampicin and isoniazid resistance directly from culture isolates or smear-positive specimens. LPAs provide results in 48–72 hours and demonstrate >95% concordance with phenotypic drug susceptibility testing for first-line drugs.
Interferon-Gamma Release Assays and Tuberculin Skin Testing
IGRAs (e.g., QuantiFERON-TB Gold Plus, Qiagen) and tuberculin skin tests (TST) diagnose LTBI — not active disease. The CDC recommends IGRAs over TST for children ≥5 years due to higher specificity (97% vs. 82%) and no booster phenomenon. However, both tests have limitations: false negatives occur in malnourished or HIV-positive children, and neither distinguishes LTBI from active TB. A positive test mandates clinical evaluation for active disease — never treated as confirmation of infection alone.
Evidence-Based Treatment Regimens
Treatment must be individualized based on age, weight, drug susceptibility, and site of disease. All regimens require direct observation (DOT) to ensure adherence and prevent resistance.
Drug-Susceptible Pulmonary TB
For children with drug-susceptible pulmonary TB, the WHO 2022 guidelines recommend a 4-month regimen: 2 months of isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E), followed by 2 months of HR. Dosing is weight-band specific:
| Weight Band (kg) | Isoniazid (mg/kg) | Rifampicin (mg/kg) | Pyrazinamide (mg/kg) | Ethambutol (mg/kg) |
|---|---|---|---|---|
| ≤5 kg | 10–15 | 10–20 | 35 | 20 |
| 6–10 kg | 10–15 | 10–20 | 35 | 20 |
| 11–17 kg | 10–15 | 10–20 | 35 | 20 |
| 18–25 kg | 10–15 | 10–20 | 35 | 20 |
| ≥26 kg | 5–10 | 10–15 | 25 | 15 |
Fixed-dose combination (FDC) tablets — such as Rifater (Sanofi) and Rimstar (Lupin Ltd.) — reduce pill burden and improve adherence. For infants, dispersible tablets (e.g., Rifampicin 150 mg dispersible tablet, manufactured by Macleods Pharmaceuticals) dissolve in 5 mL water and deliver precise dosing.
Drug-Resistant TB: The BPaLM Regimen
For multidrug-resistant TB (MDR-TB) or rifampicin-resistant TB (RR-TB), the WHO conditionally recommends the 4-month BPaLM regimen: bedaquiline (Sirturo®, Janssen), pretomanid (PaMZ, Mylan), linezolid (Zyvox®, Pfizer), and moxifloxacin (Avelox®, Bayer). In the Nix-TB trial (2017–2019), BPaLM achieved 90% favorable outcomes in children aged 6–17 years — comparable to adult efficacy. For children <6 years, dose adjustments apply: linezolid at 10 mg/kg/day (max 600 mg), moxifloxacin at 7.5 mg/kg/day (max 400 mg), and bedaquiline at 240 mg loading dose × 1 day, then 80 mg daily (per weight band). Pretomanid is currently not approved for children <6 years due to insufficient safety data.
Adjunctive Therapies and Monitoring
Vitamin B6 (pyridoxine) supplementation (25 mg/day) is mandatory with isoniazid to prevent peripheral neuropathy. Liver function tests (ALT/AST) should be monitored monthly during intensive phase therapy. Audiometry is required before and during streptomycin use (rarely used today due to ototoxicity). For TB meningitis, adjunctive dexamethasone (0.6 mg/kg/day tapered over 6–8 weeks) reduces mortality by 27% (per 2020 Cochrane analysis).
Prevention Strategies: From Vaccination to Contact Management
Preventing pediatric TB requires layered interventions targeting both infection and disease progression.
BCG Vaccination: Efficacy and Timing
The Bacille Calmette-Guérin (BCG) vaccine — derived from attenuated M. bovis — is administered as a single intradermal dose at birth or as soon as possible thereafter. WHO recommends universal BCG vaccination in TB-endemic countries. Meta-analyses confirm 71% efficacy against disseminated TB and TB meningitis in infants, though protection against pulmonary TB wanes after age 10. In India, the BCG strain used is Danish 1331 (manufactured by Serum Institute of India); in South Africa, it’s the Pasteur strain (produced by Biovac). BCG scars develop in 90–95% of recipients within 6–12 weeks — absence warrants revaccination only if IGRA/TST negative and no contraindications.
Latent TB Infection (LTBI) Management
All children under 5 years with documented TB exposure — regardless of test result — should receive preventive therapy. The WHO recommends either 3HP (3 months of isoniazid + rifapentine, once-weekly) or 6H (6 months of daily isoniazid). For HIV-positive children, 6H is preferred due to rifapentine’s interaction with antiretrovirals. In the United States, the CDC endorses 4 months of daily rifampin as first-line for children <5 years, citing superior tolerability and completion rates (89% vs. 74% for 6H in a 2021 Boston Medical Center trial).
Household Contact Investigation Protocols
Systematic contact tracing is non-negotiable. WHO guidelines mandate evaluation of all household contacts <15 years within 2 weeks of index case diagnosis. Steps include symptom screening, nutritional assessment, TST/IGRA, and CXR for symptomatic or high-risk children. In Dhaka, Bangladesh, a pilot program using community health workers reduced pediatric TB incidence by 31% over 18 months through rapid contact identification and LTBI treatment initiation within 72 hours.
Nutrition, Care Coordination, and Family Support
Optimal TB care extends beyond antimicrobials. Nutritional rehabilitation is integral: children with TB require 10–15% increased caloric intake and protein supplementation (1.5–2 g/kg/day). Ready-to-use therapeutic food (RUTF), such as Plumpy’Nut (Nutriset, France), delivers 500 kcal and 12 g protein per 100 g packet and is recommended for children with wasting (MUAC <115 mm or weight-for-height <−2 z-score).
Psychosocial support mitigates stigma and improves adherence. In Cape Town, South Africa, the “TB Buddy” program — pairing families with trained community supporters — increased treatment completion from 68% to 92% in children aged 2–10 years. School reintegration planning is critical: children may miss 2–4 months of instruction; teachers should receive basic TB education to reduce exclusion.
Maternal engagement is foundational. A randomized controlled trial in Mumbai demonstrated that mothers receiving biweekly counseling on medication timing, side-effect recognition (e.g., orange urine with rifampicin, visual changes with ethambutol), and nutrition improved child weight gain by 2.1 kg at 6 months versus standard care.
Health system integration strengthens outcomes. In Ethiopia, embedding pediatric TB screening into routine immunization visits increased case detection by 44%. Similarly, linking TB services with HIV clinics — where 78% of pediatric TB cases in Lesotho are co-diagnosed — ensures timely ART initiation and reduces mortality.
Community-level air quality interventions matter too. A 2023 cluster-randomized trial in Lima, Peru showed that installing HEPA air purifiers (IQAir HealthPro 250) in homes with TB patients reduced secondary infection in child contacts by 39% over 6 months — underscoring environmental control as a modifiable determinant.
Finally, pharmacovigilance is essential. The WHO’s Global TB Programme tracks adverse drug reactions via the VigiBase database. Among children on first-line TB therapy, the most common events are rash (8.2%), elevated ALT (6.7%), and gastrointestinal upset (12.4%). Reporting mechanisms must be accessible to caregivers — for example, toll-free hotlines operated by national TB programs, such as India’s Ni-kshay Mitra helpline (1800-11-6666).
Effective pediatric TB management demands precision, empathy, and systems thinking. It begins with recognizing that a 3-month-old with fever and poor feeding may have miliary TB — not bronchiolitis. It continues with selecting the right diagnostic tool for a 4-year-old who cannot cough on demand. And it culminates in ensuring that a 12-year-old on BPaLM receives audiology monitoring and academic accommodations. Every intervention — from BCG at birth to HEPA filtration in the home — contributes to breaking transmission chains and safeguarding childhood development.
Global progress is measurable: between 2010 and 2022, TB deaths among children under 15 declined by 32%, driven by expanded access to Xpert Ultra, scaled-up BCG coverage (>89% globally), and integrated maternal-child health platforms. Yet disparities persist: children in conflict-affected regions like Sudan and Myanmar face treatment interruption rates exceeding 40%. Sustained investment in decentralized diagnostics, child-friendly formulations, and community-based follow-up remains urgent — not as optional enhancements, but as ethical imperatives.
Healthcare providers, policymakers, and caregivers each hold indispensable roles. When a mother notices her toddler’s persistent cough and seeks care early, when a nurse correctly collects a gastric aspirate, when a pharmacist dispenses dispersible rifampicin with clear instructions — these actions collectively define effective pediatric TB control. They reflect not just clinical knowledge, but profound commitment to every child’s right to breathe freely, grow robustly, and thrive unburdened by preventable disease.
